148 related articles for article (PubMed ID: 38158932)
1. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
Beechar VB; Pouch SM; Phadke VK; Karadkhele G; Larsen CP; Woodworth MH
Transpl Infect Dis; 2024 Feb; 26(1):e14219. PubMed ID: 38158932
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cytomegalovirus "Blips" in high-risk kidney/kidney-pancreas transplant recipients.
Payne AT; Lindner BK; Gilbert AJ; Kumar RN; Thomas BS; Timpone JG
Transpl Infect Dis; 2022 Apr; 24(2):e13789. PubMed ID: 35014122
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
[TBL] [Abstract][Full Text] [Related]
6. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
[TBL] [Abstract][Full Text] [Related]
7. Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients.
Shapira G; Volkov H; Fabian I; Mohr DW; Bettinotti M; Shomron N; Avery RK; Arav-Boger R
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005904
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.
Solano C; Giménez E; Piñana JL; Albert E; Vinuesa V; Hernández-Boluda JC; Amat P; Navarro D
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28471073
[TBL] [Abstract][Full Text] [Related]
9. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies.
Huntley D; Talaya A; Giménez E; Martínez A; Hernández-Boluda JC; Hernani R; Torres I; Alberola J; Albert E; Piñana JL; Solano C; Navarro D
Biol Blood Marrow Transplant; 2020 May; 26(5):972-977. PubMed ID: 32007638
[TBL] [Abstract][Full Text] [Related]
10. Role of highly sensitive nucleic acid amplification testing for plasma cytomegalovirus DNA load in diagnosis of cytomegalovirus gastrointestinal disease among kidney transplant recipients.
Taksinwarajarn T; Sobhonslidsuk A; Kantachuvesiri S; Thongprayoon C; Cheungpasitporn W; Bruminhent J;
Transpl Infect Dis; 2021 Aug; 23(4):e13635. PubMed ID: 33982825
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients.
Sahin DG; Gunduz E; Kasifoglu N; Akay OM; Us T; Gulbas Z
Adv Ther; 2013 Aug; 30(8):784-91. PubMed ID: 23959787
[TBL] [Abstract][Full Text] [Related]
12. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients.
Vinuesa V; Bracho MA; Albert E; Solano C; Torres-Puente M; Giménez E; González-Candelas F; Navarro D
J Gen Virol; 2017 Oct; 98(10):2530-2542. PubMed ID: 28874227
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Cytomegalovirus disease and viral replication kinetics in seropositive liver transplant recipients managed under preemptive therapy in a tertiary-care center in Mexico City: a retrospective cohort study.
Fernández-García OA; García-Juárez I; Belaunzarán-Zamudio PF; Vilatoba M; Wisniowski-Yáñez A; Salomón-Ávila J; Bobadilla-Del-Valle M; Sifuentes-Osornio J; Cuellar-Rodríguez JM
BMC Infect Dis; 2022 Feb; 22(1):155. PubMed ID: 35164684
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
Navarro D; San-Juan R; Manuel O; Giménez E; Fernández-Ruiz M; Hirsch HH; Grossi PA; Aguado JM;
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28859257
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
[TBL] [Abstract][Full Text] [Related]
16. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
18. Differences in Duration and Degree of Cytomegalovirus DNAemia Observed With Two Standardized Quantitative Nucleic Acid Tests and Implications for Clinical Care.
Meesing A; Germer JJ; Yao JD; Gartner ML; Digmann BJ; Razonable RR
J Infect Dis; 2020 Jan; 221(2):251-255. PubMed ID: 31504626
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment.
Solano C; Vázquez L; Giménez E; de la Cámara R; Albert E; Rovira M; Espigado I; Calvo CM; López-Jiménez J; Suárez-Lledó M; Chinea A; Esquirol A; Pérez A; Bermúdez A; Saldaña R; Heras I; González-Huerta AJ; Torrado T; Batlle M; Jiménez S; Vallejo C; Barba P; Cuesta MÁ; Piñana JL; Navarro D;
Bone Marrow Transplant; 2021 Jun; 56(6):1281-1290. PubMed ID: 33319853
[TBL] [Abstract][Full Text] [Related]
20. CMV infection and management among pediatric solid organ transplant recipients.
Downes KJ; Sharova A; Boge CLK; Vader D; Mitrou M; Hayes M; Galetaki DM; Gianchetti L; Vella LA; Li Y
Pediatr Transplant; 2022 May; 26(3):e14220. PubMed ID: 34994041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
